GPS Vaccine-Keytruda Combo Showing Efficacy in Advanced Cancer Patients

GPS Vaccine-Keytruda Combo Showing Efficacy in Advanced Cancer Patients

282931

GPS Vaccine-Keytruda Combo Showing Efficacy in Advanced Cancer Patients

Combining the experimental vaccine galinpepimut-S (GPS) with the immune checkpoint inhibitor Keytruda (pembrolizumab) induces promising responses in people with metastatic ovarian cancer who failed one or two prior lines of treatment, early data from a Phase 1/2 trial show. The combination kept all eight patients in a first evaluated group in the trial (NCT03761914) without signs of disease progression for at least six weeks, and had a similar safety profile to that of Keytruda alone. The…

You must be logged in to read/download the full post.